This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc. The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues.

    Downloads
    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Dr. med. Diamant Thaçi

    University of Lübeck, Lübeck, Germany

    Prof. Dr. med. Diamant Thaçi is a director and full university professor at the Institute for Inflammation Medicine and Comprehensive Center for Inflammation Medicine at the University of Lübeck, Germany, a position he has held since 2013. He is chairman of the inflammatory board at the University Hospital Schleswig-Holstein, Campus Lübeck. read more

    His research experience includes basic immunology and all stages of clinical drug development, especially in chronic inflammatory skin diseases such as atopic dermatitis, hidradenitis suppurativa and psoriasis. He has been involved in numerous investigator-driven trials, and acted as main investigator on many national and international multicentre trials. In addition to his clinical commitments, Prof. Dr. Thaçi is a lecturer in dermatology and cross-section immunology/microbiology.

    Prof. Dr. Thaçi is a steering committee member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), and an active member of the International Psoriasis Council (IPC), International Eczema council (IEC) and Skin Inflammation & Psoriasis International Network (SPIN). He has been a recipient of the Theodor-Stern Foundation Award for excellent clinical research.    

    Prof. Dr. Thaçi has authored numerous articles in high-tier journals such as the New England Journal of Medicine and The Lancet and is the editor, co-editor and editorial board member of several journals. He also serves as a scientific reviewer for dermatological and general medicine journals.

    Prof. Dr. med. Diamant Thaçi discloses Advisory board/panel fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Consultancy fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Grants/research support from AbbVie, Leo and Novartis. Speaker’s bureau fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Roche-Posay, Sanofi and UCB.
    Dr Benjamin Ungar

    Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Dr Benjamin Ungar is an assistant professor in the Department of Dermatology at Icahn School of Medicine at Mount Sinai, New York, USA and in 2023 became the Director of the Alopecia Center of Excellence at Mount Sinai. read more

    Dr Ungar graduated from Harvard University cum laude in 2009 and began medical school at the Icahn School of Medicine in 2011. From 2014 to 2016, he completed a research fellowship in the Laboratory for Investigative Dermatology at Rockefeller University, after which he graduated from Medical School in 2017 with distinction in research. 

    After completing his intern year at NYU Winthrop Hospital, Dr Ungar began his dermatology residency at Mount Sinai, from which he graduated as the Chief Resident in June 2021. During the last year of his residency, Dr Ungar completed a T32 NIH Research Training Fellowship.

    Dr Benjamin Ungar discloses Advisory board/panel fees from Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi and UCB. Grants/research support from Bristol Myers Squibb, Incyte, Pfizer, Rapt Therapeutics and Sanofi.
    Back to Faculty
    touchIMMUNOLOGY touchIMMUNOLOGY
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    How do you most often manage patients affected by acne as a result of systemic tx?

    Submit your answer to see the results

    Stop systemic therapy
       
    Switch to another systemic therapy
       
    Prescribe a topical or systemic therapy for acne
       
    Other/A combination of the above
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which systemic tx do you use most often in paediatric pts with moderate–severe AD?

    Submit your answer to see the results

    Anti-IL-13 monoclonal antibody therapy
       
    Anti-IL-4Rα monoclonal antibody therapy
       
    Tyrosine kinase inhibitor therapy
       
    Off-label systemic therapy/Never use systemic therapy
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    Which of these burdens of AD tend to impact your paediatric patients the most?

    Submit your answer to see the results

    Mental health/psychological burden
       
    Impact on sleep and activities of daily living
       
    Treatment burden
       
    Other
       
     
    Understanding and assessing disease severity in children and adolescents with AD
    Selection of systemic therapy for children and adolescents with moderate–severe AD
    Practical management of side effects of systemic treatments for moderate–severe AD
    Take CE/CME Test
    Atopic Dermatitis, Dermatological Conditions, Paediatric Dermatology CE/CME accredited

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Simplified Chinese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Assess disease burden in paediatric patients with atopic dermatitis, including those affected on the hands and feet
    • Select systemic therapies for individual paediatric patients with moderate-to-severe atopic dermatitis based on the latest efficacy and safety data in the context of patient-specific factors
    • Apply effective strategies for monitoring and managing key side effects associated with systemic therapies for moderate-to-severe atopic dermatitis in paediatric patients
    Overview

    In this activity, dermatologists with expertise in atopic dermatitis (AD) respond to questions from the dermatology, immunology, paediatrics and primary care communities on managing moderate-to-severe AD in children and adolescents, including assessing the severity of AD, selecting systemic therapy and managing the potential side effects of systemic treatment.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Allergists, dermatologists, dermatology nurses/nurse practitioners, immunologists, paediatric dermatologists, paediatricians and primary care physicians involved in the management of atopic dermatitis.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Dr. med. Diamant Thaçi discloses: Advisory board/panel fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Consultancy fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis, Pfizer and UCB. Grants/research support from AbbVie, Leo and Novartis. Speaker’s bureau fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Roche-Posay, Sanofi and UCB.

    Dr Benjamin Ungar discloses: Advisory board/panel fees from Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi and UCB. Grants/research support from Bristol Myers Squibb, Incyte, Pfizer, Rapt Therapeutics and Sanofi.

    Content Reviewer

    Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Contributor

    Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 0.75 contact hour may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.

    Date of original release: 01 October 2024. Date credits expire: 01 October 2025.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hours of effective education time.

    The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Time to complete: 48 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Simplified Chinese, Portuguese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchFOCUS

    Addressing the diagnosis and management of pet allergies in primary care and beyond

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis

    GO TO HUB

    touchIN CONVERSATION

    Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Andrew Blauvelt, Dermatology Meeting News 2021: Abrocitinib JADE REGIMEN Trial

    GO TO HUB

    Topics covered in this activity

    Atopic Dermatitis / Dermatological Conditions / Paediatric Dermatology
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from Sanofi and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    USF Health

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 01 October 2024. Date credits expire: 01 October 2025.

    Claim Credit
    touchIN CONVERSATION
    Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
    0.75 CE/CME credit
    Question 1/4
    In a recent real-world study of the impact of atopic dermatitis on quality of life, what proportion of paediatric patients (age 0–11 years) reported a moderate or extreme impact of a flare on playing with or meeting friends?

    Recent patient/caregiver survey data on the impact of flares on quality of life in paediatric (0–11 years, n=221) and adolescent (12–17 years, n=228) patients with moderate-to-severe atopic dermatitis, showed that 67% of paediatric patients and 80% of adolescents reported a moderate or extreme impact of flares on ‘playing with or meeting friends’.

    Reference

    Eichenfield L, et al. J Am Acad Dermatol. 2024;91(Suppl.):AB91.

    Question 2/4
    When considering tools to assess atopic dermatitis, which of these outcomes will you consider most important to define the severity of disease?

    Clinical measures are important to define the severity of atopic dermatitis. Measures can be objective (physician-assessed disease severity) or subjective (patient-reported symptoms and quality of life outcomes). Both are important to assess, alongside clinical signs and characteristics, including location of the affected areas, in the overall judgement of disease severity. Tools commonly used for assessing atopic dermatitis severity include body surface area (BSA); Dermatology Life Quality Index (DLQI); Eczema Area and Severity Index (EASI); Patient Oriented Eczema Measure (POEM); pruritus Numerical Rating Scale (NRS); and SCORing Atopic Dermatitis (SCORAD). 

    Reference

    Gooderham MJ, et al. J Cutan Med Surg. 2018;22(Suppl.1):10S–16S.

    Question 3/4
    Your patient is a 16-year-old with moderate atopic dermatitis historically managed with topical therapies. Your patient explains that in recent months they’ve been experiencing more severe flare ups, with increasingly dry and itchy skin that is prone to cracking. They ask you if there are any other treatments available, as they are worried about the discomfort, and potential scarring. Based on updates reported at AAD 2024, which of the following might you consider next in the management of this patient?

    AAD, American Academy of Dermatology.

    Data presented at the American Academy of Dermatology 2024 congress showed that dupilumab improved skin barrier function and PROs. In the phase IV PELISTAD study, patients aged 6–11 yrs with moderate-to-severe atopic dermatitis treated with dupilumab (N=23) achieved improved median transepidermal water loss after 16 weeks vs baseline (28.1 g/m2/h; p<0.0001), that persisted to week 28 in both lesional (20.9 g/m2/h) and non-lesional (16.0 g/m2/h) skin (both p<0.01 vs baseline). Improvements in mean PRO scores at week 28 vs baseline were achieved, as measured by both the EASI (6.5 vs 34.8) and WI-NRS (2.0 vs 7.6), where a decrease in score indicates improvement.1,2

    Abbreviations

    EASI, Eczema Area and Severity Index; PRO, patient-reported outcome; WI-NRS, Worst Itch Numerical Rating Scale.

    References

    1. Cork MJ, et al. J Am Acad Dermatol. 2024;91(Suppl.):AB34.
    2. Cork MJ, et al. Presented at: 2024 AAD Annual Meeting, San Diego, CA, USA. 8–12 March 2024. Poster #53081.
    Question 4/4
    Your patient is a 14-year-old with severe atopic dermatitis. Following discussions with the child and their parents, you are about to initiate treatment with a systemic biologic therapy, as current topical therapies are not achieving adequate disease control. Which of the following would you consider including as part of the patient’s management plan?

    Conjunctivitis is a known side effect of systemic biologic therapies, alongside injection-site reactions.1,2 Nasopharyngitis and infections are associated with systemic Janus kinase inhibitor therapies.1

    Patients with conjunctivitis may experience dry and itchy red eyes, tearing and foreign body sensation, and an eczematous rash around the eyes. Previous history of conjunctivitis and more severe atopic dermatitis prior to initiation of systemic biologic therapy may be risk factors for conjunctivitis on treatment.2 According to American2 and European guidelines,3 some clinical protocols suggest a baseline ophthalmology examination and the use of lubricant eye drops when biologic therapy is initiated; however, it should be noted that practices may vary.2,3

    References

    1. Butala S, Paller AS. J Allergy Clin Immunol. 2023;151:681–5.
    2. Chu DK, et al. Ann Allergy Asthma Immunol. 2024;132:274−312.
    3. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36:1409–31.
    Back to Activity

    You may also be interested in...

    Raj Chovatiya Baricitinib

    CONFERENCE HUB

    Raj Chovatiya, Dermatology Meeting News 2023: JAK inhibitor treatment & monitoring guidelines in inflammatory dermatologic diseases

    GO TO HUB

    CONFERENCE HUB

    Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis

    GO TO HUB

    touchTALKS

    Growing up with atopic dermatitis: Achieving sustained outcomes for moderate-to-severe disease

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchEXPERT OPINIONS

    Immunotherapy and evolving approaches for basal cell carcinoma

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    This activity is funded by:

    An independent medical education grant from Sanofi and Regeneron Pharmaceuticals. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    USF Health

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    EBAC®

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 01 October 2024. Date credits expire: 01 October 2025.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup